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Abstract
The main objectives of tuberculosis therapy are to cure the patients and to minimize the possibility of transmission 
of the bacillus to healthy subjects. Adverse effects of antituberculosis drugs or drug interactions (among 
antituberculosis drugs or between antituberculosis drugs and other drugs) can make it necessary to modify or 
discontinue treatment. We briefly review the new guidelines for the pharmacological treatment of tuberculosis, 
introduced by the Brazilian National Ministry of Health in 2009, and describe the general mechanism of action, 
absorption, metabolization, and excretion of the first-line drugs used in the basic regimen. We describe adverse 
drug reactions and interactions (with other drugs, food, and antacids), as well as the most appropriate approach 
to special situations, such as pregnancy, breastfeeding, liver failure, and kidney failure. We also describe the 
mechanisms by which the interactions among the antituberculosis drugs used in the basic regimen can cause drug-
induced hepatitis, and we discuss the alternatives in this situation.
Keywords: Tuberculosis; Drug interactions; Antibiotics, antitubercular; Pharmacologic actions; Drug toxicity; 
Drug-induced liver injury.
Resumo
Os objetivos principais do tratamento da tuberculose são curar o paciente e minimizar a possibilidade de transmissão 
do bacilo para indivíduos saudáveis. Reações adversas ou interações das drogas antituberculose entre si e com 
outros fármacos podem causar modificação ou descontinuação da terapêutica. Revisamos sucintamente o novo 
tratamento farmacológico da tuberculose introduzido pelo Ministério da Saúde do Brasil em 2009 e mostramos 
os mecanismos gerais de ação, absorção, metabolização e excreção dos medicamentos utilizados no esquema 
básico. Descrevemos as reações adversas e as interações (com medicamentos, alimentos e antiácidos) assim como a 
abordagem mais adequada para situações especiais, como gravidez, amamentação, insuficiência hepática e renal. 
Também descrevemos os mecanismos pelos quais as interações das drogas antituberculose do esquema básico 
podem causar hepatite medicamentosa e as possíveis alternativas nessa situação.
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Toxicidade de drogas; Doença hepática induzida por drogas.
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Introduction
In Brazil, tuberculosis treatment regimens 
have been standardized by the Brazilian National 
Ministry of Health since 1979. According to the 
latest technical norms, published in October 
of 2009, the treatment recommended for all 
new cases of pulmonary and extrapulmonary 
tuberculosis, as well as for all cases of recurrence 
and retreatment due to noncompliance, is the 
use of a fixed-dose, single-tablet combination 
of rifampin, isoniazid, pyrazinamide, and 
ethambutol for two months and, in the 
second phase, a combination of isoniazid and 
rifampin for another four months (2RHZE/4RH 
regimen).(1,2) In cases of meningoencephalitis 
due to tuberculosis, the same initial regimen, 
with the addition of a corticosteroid in the 
first month of treatment, is recommended. 
The second phase extends for seven months. 
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Adverse reactions that are more severe 
contribute to changes in the therapeutic 
regimen and lead to the use of drugs that 
are less active and occasionally more toxic,(8,9) 
substantially increasing treatment costs, as well 
as the number of home visits, outpatient visits, 
and hospitalizations.(10) These reactions can lead 
patients to interrupt or abandon treatment,(11) 
resulting in higher rates of treatment failure and 
acquired resistance, as well as an increase in the 
number of tuberculosis cases(12) and, more rarely, 
in the number of deaths.(13)
According to the Brazilian National Ministry 
of Health, the incidence of minor or mild 
adverse reactions in patients treated with the 
former regimen I (2RHZ/4RH) ranged from 5% 
to 20% and did not result in immediate change 
in the standard regimen. Major or severe adverse 
reactions were less common (occurring in 
approximately 2% of the cases, reaching 8% in 
specialized clinics) and led to the discontinuation 
or alteration of the treatment. Minor adverse 
effects include nausea, vomiting, epigastric pain, 
abdominal pain, arthralgia, arthritis, peripheral 
neuropathy, cutaneous pruritus, headache, 
and changes in behavior (insomnia, anxiety, 
decreased libido, and euphoria). Major adverse 
effects include exanthema, vertigo, psychosis, 
and hepatotoxicity (vomiting, alteration in liver 
function tests, and hepatitis). However, a recent 
study investigating 329 medical charts of patients 
from a teaching hospital reported that 41.1% 
of the patients presented with minor adverse 
reactions and 12.8% presented with major 
adverse reactions.(14) The difference between 
the results suggests that, during the everyday 
monitoring in clinical practice, not all possible 
side effects are investigated. Perhaps these effects 
occur in such a mild or even transitory way that 
patients do not consider them relevant enough 
to be reported to the physicians.(14) In addition, 
it is often difficult to evaluate the effectiveness 
or toxicity of a given drug, since antituberculosis 
drugs are usually administered as a combination 
regimen of various drugs, which requires that 
health care workers have a thorough knowledge 
of the pharmacodynamics and possible side 
effects of the drugs used in combination, as well 
as of the interactions among those drugs.
In this review article, we describe the 
principal characteristics of each of the drugs that 
constitute the basic regimen for tuberculosis 
treatment proposed by the Brazilian National 
Ministry of Health and the Brazilian Thoracic 
A number of treatments have been proposed 
for cases of intolerance to one of the first-line 
drugs and for other clinical situations, such as 
liver disease.(1,2)
Patients with bacilli that are resistant to 
isoniazid and rifampin, patients with bacilli 
that are resistant to isoniazid, rifampin, and 
another first-line drug, and patients in whom 
the basic regimen fails constitute a group 
of patients classified as having multidrug-
resistant tuberculosis. For cases such as these, 
a combination regimen of streptomycin, 
ethambutol, terizidone, pyrazinamide, and one 
quinolone (levofloxacin or ofloxacin) has been 
proposed.(1,2) If streptomycin cannot be used, it 
should be replaced with amikacin.(1,2) Patients 
with extensively drug-resistant tuberculosis 
should be referred to a tertiary referral center, 
and individualized salvage drug regimens 
(which include capreomycin, moxifloxacin, para-
aminosalicylic acid, and ethionamide) should be 
used.(2)
Chart 1 shows the recommended doses of 
the aforementioned drugs according to the 
Brazilian National Ministry of Health/Brazilian 
Thoracic Association,(1,2) the American Thoracic 
Society (ATS)/Centers for Disease Control and 
Prevention (CDC)/Infectious Diseases Society 
of America (IDSA),(3) and the World Health 
Organization (WHO).(4,5)
Although the therapeutic regimens are 
extremely effective, studies have shown 
that undesirable drug interactions (among 
the antituberculosis drugs or between the 
antituberculosis drugs and other drugs used by 
patients) can occur, as can adverse reactions of 
varying degrees of severity.(3)
Drug interactions can be defined as reciprocal 
reactions among drugs, resulting in undesirable 
or unexpected effects. Drug interactions can alter 
the serum concentrations of the drugs involved, 
thereby reducing their effectiveness.(6)
Adverse reactions to antituberculosis drugs 
are related to various factors, and the principal 
determinants of such reactions are the dose 
and time of day at which the medication 
is administered, as well as patient age and 
nutritional status, together with the presence 
of preexisting diseases or dysfunctions, such as 
alcoholism, impaired liver function, impaired 
kidney function, and HIV coinfection.(7)
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Chart 1 - Drug doses recommended by the Brazilian National Ministry of Health/Brazilian National Tuberculosis 
Control Program/Brazilian Thoracic Association, American Thoracic Society/Centers for Disease Control and 
Prevention/Infectious Diseases Society of America, and World Health Organization.
Drug Type of 
patient
NMH/NTCP/BTA(1,2) ATS/CDC/IDSA(3) WHO(4.5)
Daily dose
Rifampin Adults 35-50 kg: 450 mg 10 mg/kg  
(maximum of 600 mg)
10 mg/kg  
(8-12 mg/kg; maximum of 600 mg)>50 kg: 600 mg
Children and 
adolescents
10 mg • kg−1 • day−1 10-20 mg/kg  
(maximum of 600 mg)
10 mg/kg  
(8-12 mg/kg; maximum of 600 mg)20-35 kg: 300 mg
Isoniazid Adults 35-50 kg: 225 mg 5 mg/kg  
(maximum of 300 mg)
5 mg/kg  
(4-6 mg/kg; maximum of 300 mg)>50 kg: 300 mg
Children and 
adolescents
10 mg • kg−1 • day−1 10-15 mg/day  
(maximum of 300 mg)
5 mg/kg  
(4-6 mg/kg; maximum of 300 mg)20-35 kg: 150 mg
Pyrazinamide Adults 36-50 kg: 1,200 mg 20-25 mg/kg  
(maximum of 2,000 mg)
25 mg/kg  
(20-30 mg/kg)>50 kg: 1,600 mg
Children and 
adolescents
35 mg • kg−1 • day−1 15-30 mg/kg  
(maximum of 2,000 mg)
25 mg/kg  
(20-30 mg/kg)20-35 kg: 800 mg
Ethambutola Adults 36-50 kg: 825 mg  
(800 mg for MDR-TB)
15-20 mg/kg  
(maximum of 1,600 mg)
15 mg/kg  
(15-20 mg/kg)
> 50 kg: 1,100 mg  
(1.200 mg for MDR-TB)
Children and 
adolescents
Up to 20 kg: 7.5-10 mg/kg 15-20 mg/kg  
(maximum of 1,000 mg)
15 mg/kg
21-35 kg: 550 mg  
(400-800 mg for MDR-TB)
Streptomycin Adults 36-50 kg: 750-1,000 mg 15 mg/kg  
(maximum of 1,000 mg)
15-20 mg/kg  
(maximum of 1.000 mg)
> 50 kg: 1,000 mg > 60 years of age:  
maximum of 750 mg/dia
> 60 years of age,  
< 50 kg: maximum of  
500-750 mg/day
Children and 
adolescents
Up to 20 kg: 15-20 mg/kg 20-40 mg/kg  
(maximum of 1,000 mg)
20-40 mg/kg
21-35 kg: 500 mg/day
Amikacin / 
Kanamycin
Adults  15 mg/kg  
(maximum of 1,000 mg)
15-20 mg/kg  
(maximum of 1,000 mg)
> 60 years of age: maximum 
of 750 mg
Usually 750-1,000 mg/day
Children and 
adolescents
 15-30 mg/kg  
(maximum of 1,000 mg/day)
15-30 mg/kg
Ofloxacina Adults 20-50 kg: 400 mg  15-20 mg/kg. 
> 50 kg: 800 mg Usually 800 mg/day
Children and 
adolescents
10 mg/kg  15-20 mg/kg
Levofloxacina Adults 36-50 kg: 500-750 mg 500-1,000 mg/day 7,5-10 mg/kg
> 50 kg: 750 mg Usually 750 mg/ day
Children and 
adolescents
Up to 20 kg: 7.5-10 mg/kg  7.5-10 mg/kg
21-35 kg: 250-500 mg
Moxifloxacina Adults  400 mg/day 7.5-10 mg/kg
Usually 400 mg/day
Children and 
adolescents
  7.5-10 mg/kg
Cycloserine / 
Terizidone 
Adults 36-50 kg: 750 mg 10-15 mg/kg  
(maximum of 1,000 mg)
10-15 mg/kg  
(maximum of 1,000 mg)
> 50 kg: 750 mg Usually 500-750 mg/day Usually 500-750 mg/day
Children and 
adolescents
Up to 20 kg: 15-20 mg/kg 10-15 mg/kg  
(maximum of 1,000 mg)
10-20 mg/kg
21-35 kg: 500 mg
NMH: (Brazilian) National Ministry of Health; NTCP: (Brazilian) National Tuberculosis Control Program; BTA: Brazilian Thoracic Association; 
ATS: American Thoracic Society; CDC: Centers for Disease Control and Prevention; IDSA: Infectious Diseases Society of America; WHO: World 
Health Organization; and MDR-TB: multidrug-resistant tuberculosis. aDrugs that should be used with caution in children.
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Metabolization and excretion
Isoniazid is metabolized in the liver through 
acetylation by N-acetyltransferase, which 
produces acetylisoniazid and isonicotinic acid. 
The acetylation rate is a genetic characteristic 
and therefore varies from patient to patient. 
Certain patients present the rapid acetylator 
phenotype, whereas others present the slow 
acetylator phenotype. There is controversy as 
to whether the latter are more likely to develop 
manifestations of hepatotoxicity than are the 
former, there being no differences between 
these phenotypes in terms of antimicrobial 
activity. Isoniazid is excreted by the kidney 
(70-96%), generating, for the most part, inactive 
metabolites. In patients with the rapid acetylator 
phenotype, 7% of the isoniazid excreted in urine 
can appear as free isoniazid, whereas 37% can 
appear as conjugated isoniazid in patients with 
the slow acetylator phenotype. A small proportion 
is excreted in feces. The half-life of isoniazid is 
approximately 1 h (range: 0.5-1.6 h) in patients 
with the rapid acetylator phenotype and 2-5 h 
in those with the slow acetylator phenotype; in 
patients with liver disease or kidney failure, the 
half-life of isoniazid can be even longer.(16,18)
Central nervous system 
The cerebrospinal fluid (CSF) and plasma 
concentrations of isoniazid are similar.(3)
Association,(1,2) as well as the relevant aspects of 
the pharmacokinetics of the drugs in order to 
understand the mechanisms of interaction and 
possible adverse effects.
Isoniazid
Isoniazid is one of the most important drugs 
in the treatment of tuberculosis. It has been used 
since 1952. The structure of isoniazid is simple. It 
comprises a pyridine ring and a hydrazine group. 
The minimum inhibitory concentration (MIC) 
of isoniazid for Mycobacterium tuberculosis 
is 0.02-0.20 µg/mL. Although isoniazid has a 
bactericidal effect on rapidly growing bacilli, it 
has a limited effect on slow-growing (generally 
intracellular) and intermittently growing 
(generally extracellular) bacilli.(15,16)
Mechanism of action
Isoniazid is a prodrug and must be activated by 
the M. tuberculosis catalase-peroxidase enzyme 
KatG; the activation of isoniazid produces 
oxygen-derived free radicals (superoxide, 
hydrogen peroxide, and peroxynitrite) and 
organic free radicals that inhibit the formation 
of mycolic acids of the bacterial cell wall, 
causing DNA damage and, subsequently, 
the death of the bacillus. The most common 
mechanism of resistance to isoniazid consists of 
KatG mutations, which decrease the activity of 
isoniazid and prevent the prodrug from being 
converted into its active metabolite.(15,17)
Drug Type of 
patient
NMH/NTCP/BTA(1,2) ATS/CDC/IDSA(3) WHO(4.5)
Daily dose
Ethionamide Adults  15-20 mg/day  
(maximum of 1,000 mg/ day)
15-20 mg/kg  
(maximum of 1,000 mg)
Usually 500-750 mg/day Usually 500-750 mg/day
Children and 
adolescents
 15-20 mg/day  
(maximum of 1,000 mg/day)
15-20 mg/kg
Capreomycin Adults  15 mg/kg  
(maximum of 1,000 g/day). 
15-20 mg/kg
> 60 years of age:  
maximum of 750 mg/day
Usually 1,000 mg/day
Children and 
adolescents
 15-30 mg/day  
(maximum of 1,000 mg/day)
15-30 mg/kg
Para-
aminosalicylic 
acid
Adults  8-12 g/day 150 mg/kg
Usually 10-12 g/day
Children and 
adolescents
 200-300 mg/kg 150 mg/kg
NMH: (Brazilian) National Ministry of Health; NTCP: (Brazilian) National Tuberculosis Control Program; BTA: Brazilian Thoracic Association; 
ATS: American Thoracic Society; CDC: Centers for Disease Control and Prevention; IDSA: Infectious Diseases Society of America; WHO: World 
Health Organization; and MDR-TB: multidrug-resistant tuberculosis. aDrugs that should be used with caution in children.
Chart 1 - Continued...
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manifestations are less common, more 
severe, and often difficult to diagnose. 
The differential diagnosis with tuberculous 
meningitis and hepatic encephalopathy 
should be established. Attempted suicides 
have been reported to occur among 
patients using isoniazid.(24-26) 
• Hematological alterations or vasculitis: 
Hematological alterations and vasculitis 
are rare complications of isoniazid 
administration and occur due to 
hypersensitivity.(23) 
• Peripheral neuropathy: Peripheral neuro­
pathy occurs in approximately 20% of 
patients treated with isoniazid. It is dose-
dependent and uncommon at a dose of 
5 mg • kg−1 • day−1. It is more common 
at doses higher than 300 mg/day. The risk 
of polyneuritis increases in the presence of 
associated conditions, such as advanced 
age, diabetes mellitus, alcoholism, 
nutritional deficiency, slow acetylator 
phenotype, HIV infection, kidney failure, 
pregnancy, and breastfeeding. Patients can 
be treated prophylactically with pyridoxine, 
at a dose of 25-50 mg/day. Patients who 
develop polyneuritis should be treated with 
100-200 mg/day of pyridoxine.(3,5,27,28) 
• Clinical hepatitis: Recent studies have 
shown that the incidence of clinical 
hepatitis in patients receiving isoniazid is 
lower than previously thought. A meta-
analysis of six studies investigating the 
use of isoniazid in isolation reported 
that the incidence of hepatitis was 0.6%. 
When isoniazid was used in combination 
with rifampin, the incidence of hepatitis 
was 2.7%. In patients using isoniazid in 
isolation, the risk of developing hepatitis 
increases with age. The disease is rare in 
individuals under 20 years of age. However, 
in patients in the 50-64 year age bracket, 
the risk of developing hepatitis can be 
as high as 2%. The risk also increases in 
individuals with previous liver disease, 
in individuals who drink alcohol daily or 
who are heavy drinkers, and in women in 
the immediate postpartum period. Fatal 
hepatitis is extremely rare and occurs 
in less than 0.023% of the cases. The 
treatment must be discontinued, and, in 
patients using multiple-drug regimens, the 
Adverse effects
Isoniazid, when used in isolation for tuber-
culosis prophylaxis (at a dose of 10 mg • kg−1 • 
day−1, up to 300 mg), rarely causes side effects 
in individuals without liver disease or kidney 
failure.(3) If isoniazid is used in combination with 
other drugs for the treatment of tuberculosis, 
this is the dose that is currently recommended 
in Brazil.(1,2)
Minor adverse effects
• Nausea, vomiting, and epigastric pain: 
Although uncommon, nausea, vomiting, 
and epigastric pain can occur at the 
initiation of treatment with isoniazid when 
the drug is used in isolation for tuberculosis 
chemoprophylaxis. Taking the drug 2 h 
after the first meal and using symptomatic 
medication (metoclopramide, ranitidine, or 
omeprazole) can relieve the symptoms.(7) 
• Transitory and asymptomatic increase in 
hepatic enzyme levels: In 10-20% of the 
patients who use isoniazid in isolation, 
there is an up to three-fold increase over 
the normal serum levels of the enzyme 
alanine aminotransferase (formerly known 
as glutamic-pyruvic transaminase), which 
is more specific for liver damage than is 
aspartate aminotransferase (formerly known 
as glutamic-oxaloacetic transaminase). 
Those levels normalize as the treatment 
continues.(3,19-22) 
• Arthralgia: Arthralgia is a rare complication 
of isoniazid administration and responds 
to treatment with nonsteroidal anti-
inflammatory drugs.(7,23) 
• Changes in behavior: Headache, insomnia, 
euphoria, agitation, anxiety, and 
somnolence can occur in patients receiving 
isoniazid.(7,23) 
• Acne: Acne on the face and torso is a 
common manifestation that disappears 
when isoniazid is discontinued.(23) 
• Cutaneous pruritus or fever: Patients 
report developing cutaneous pruritus or 
fever after taking isoniazid.(23) 
Major adverse effects
• Psychosis, convulsive seizures, mental 
confusion, and coma: In patients receiving 
isoniazid, neurological and psychiatric 
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carbohydrates, can decrease the absorption of 
the drug by as much as 57% and the plasma 
concentration of the drug by as much as 30%. The 
drug should not be taken with fluids containing 
excess glucose or lactose. Isoniazid inhibits the 
monoamine oxidase enzyme, which is why the 
drug should not be taken concomitantly with 
foods rich in tyramine and histamine, such as 
certain types of cheese (Swiss and Cheshire), 
fish (tuna and herring), and alcohol, especially 
red wine. The symptoms of these interactions 
include palpitation, sweating, flushing of the 
face, chills, headache, diarrhea, erythema, and 
pruritus.(35)
Antacids
Drugs that increase the gastric pH delay the 
absorption of isoniazid. Antacids containing 
aluminum hydroxide or ranitidine should be 
administered 1 h after the administration of 
isoniazid.(35)
Other drugs
Isoniazid is an inhibitor of the cytochrome 
P450 (CYP450) system families CYP2C9, 
CYP2C19, and CYP2E1, but its effect on the 
CYP3A family is minimal. This inhibitory effect of 
isoniazid can increase the plasma concentrations 
of certain drugs to toxic levels.(3,36) The plasma 
concentrations of anticonvulsants, such as 
phenytoin and carbamazepine, can increase 
when these drugs are used in combination 
with isoniazid.(37) The same occurs with the 
benzodiazepines that are metabolized by 
oxidation (e.g., diazepam and triazolam), as well 
as with theophylline, valproic acid, disulfiram, 
acetaminophen, and oral anticoagulants. The 
combination of isoniazid and levodopa can 
cause hypertension, palpitation, and flushing of 
the face.(3,5,6,38)
Rifampin
Rifampin is the most important drug in the 
treatment of tuberculosis. The drug has been 
used since 1966 and the MIC of rifampin for 
M. tuberculosis is 0.05-0.50 µg/mL.(15) Rifampin 
is a bactericidal drug that kills growing, 
metabolically active bacilli, as well as bacilli in 
the stationary phase, during which metabolism is 
reduced. When rifampin is used in combination 
with pyrazinamide, tuberculosis treatment 
duration can be reduced to six months.(3)
causative drug must be identified (see also 
Hepatotoxicity).(3,7,19-22) 
• Lupus­like syndrome: Patients receiving 
isoniazid can develop antinuclear antibodies 
during the use of the drug. Less than 1% 
develop systemic lupus erythematosus, the 
incidence of which is the same in both 
genders. Isoniazid administration can also 
worsen preexisting lupus.(3,29,30)
Use during pregnancy
Isoniazid is a category C drug. Isoniazid use 
during pregnancy is considered safe. However, 
there is a risk of developing hepatitis in the 
postpartum period. The WHO recommends that 
all pregnant women receiving isoniazid also take 
pyridoxine (25-50 mg/day). Neonates born to 
mothers who have been under treatment with 
isoniazid are at risk of developing convulsive 
seizures.(3,5,31)
Use during breastfeeding
Although isoniazid is considered compatible 
with breastfeeding, the infant should be 
monitored for jaundice.(32)
Use in patients with liver failure
Isoniazid is a hepatotoxic drug, the effect 
of which becomes more evident in individuals 
with liver disease, in alcoholic individuals, and in 
individuals over 50 years of age. In such patients, 
the half-life of isoniazid is longer, and the serum 
levels of the drug are higher. These patients 
should be closely monitored and should undergo 
clinical examination and laboratory tests more 
frequently than is necessary for patients without 
liver disease.(3,33)
Use in patients with kidney failure
Adjustments to the doses of isoniazid are 
not required in patients with kidney failure or in 
those on hemodialysis.(3,4,34)
Interactions
Foods
Isoniazid should be taken on an empty 
stomach because it requires an acid medium 
in order to be absorbed. Foods, particularly 
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discoloration of body fluids. Orange-
colored tears can stain contact lenses. 
• Skin reaction: Pruritus, with or without 
erythema, occurs in 6% of patients 
receiving rifampin. This reaction is generally 
mild and, in most cases, does not warrant 
treatment discontinuation. It might be 
necessary to use topical or systemic 
medication (moisturizers, antihistamines, 
or even corticosteroids). 
• Flu­like syndrome: Flu­like syndrome is rare 
and occurs in patients who use intermittent 
regimens that include rifampin. 
• Fatigue, dizziness, headache, dyspnea, and 
ataxia can also occur in patients treated 
with rifampin. 
Major adverse effects
• Exanthema: Exanthema can occur due to 
the use of rifampin or of another drug 
administered in combination with rifampin. 
If exanthema occurs, treatment should be 
discontinued, and the drugs should be 
subsequently reintroduced, one by one, in 
order to identify the causative drug. 
• Hepatotoxicity: Transitory and asymp­
tomatic increases in the serum levels of 
bilirubin and hepatic enzymes occur in 5% 
of patients treated with rifampin. Those 
levels subsequently normalize, without 
the need to discontinue the treatment. 
However, cholestatic hepatitis occurs in 
2.7% of the patients receiving rifampin 
in combination with isoniazid and in up 
to 1.1% of those receiving rifampin in 
combination with antituberculosis drugs 
other than isoniazid. 
• Immunological reactions: Thrombocyto­
penia, leukopenia, eosinophilia, hemolytic 
anemia, agranulocytosis, vasculitis, acute 
interstitial nephritis, and septic shock 
can occur after rifampin administration. 
These reactions are rare and occur in less 
than 0.1% of the patients. However, these 
reactions are severe and call for a change 
in the therapeutic regimen. 
Use during pregnancy
Rifampin is a category C drug. Rifampin has 
been used during pregnancy, and no teratogenic 
effects have been reported.(3,5,31) As a precaution, 
Mechanism of action
Rifampin inhibits the gene transcription of 
mycobacteria by blocking the DNA-dependent 
RNA polymerase, which prevents the bacillus 
from synthesizing messenger RNA and protein, 
causing cell death.(39) Resistance to rifampin 
occurs due to mutations in the rpoB gene, which 
encodes the RNA polymerase beta chain.(15,39)
Metabolization and excretion
The serum and plasma levels of rifampin 
peak at 5-10 µg/mL within 2-4 h after the 
oral ingestion of a 600-mg dose of the drug. 
Approximately 85% of the drug is metabolized 
in the liver through microsomal enzymes of 
the CYP450 system. The drug is excreted via 
the biliary tract (60-65%). Part of rifampin 
(6-15%) is excreted in unmetabolized form 
and is reabsorbed in the intestine, progressively 
increasing the serum levels of the drug. After 
approximately 14 days, enzymes that increase 
the metabolism of the drug are produced 
(autoinduction of metabolism), and the half-
life of rifampin is reduced from 3-5 h to 2-3 h. 
A smaller proportion of the drug is excreted in 
urine.(40,41)
Central nervous system 
The concentration of rifampin in the central 
nervous system is only 10-20% of the serum 
concentration of the drug. However, it is enough 
for the drug to be clinically effective. The 
concentration increases during meningitis.(3)
Adverse effects(3-5,7)
Minor adverse effects
• Gastrointestinal reactions: Nausea, 
anorexia, and abdominal pain can occur 
in patients treated with rifampin. The 
incidence of gastrointestinal reactions 
varies. However, the symptoms are rarely 
severe enough to warrant discontinuation 
of the drug. Gastrointestinal reactions 
can be treated as previously described for 
isoniazid. 
• Orange­colored tears, sweat, and urine: 
Patients should be alerted to the possibility 
that rifampin administration can cause 
Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations.  
Part 1: First-line drugs
J Bras Pneumol. 2010;36(5):626-640
633
uridine diphosphate-glucuronosyltransferase, 
an enzyme that has also been implicated in the 
metabolism of various drugs, the plasma levels 
of which can be reduced when such drugs are 
administered in combination with rifampin.(43,44)
The possibility of interaction between 
rifampin and other drugs calls for a thorough 
history taking that focuses on the drugs currently 
used by patients. There is a decrease in the 
plasma concentrations of the following drugs 
when administered concomitantly with rifampin: 
oral hypoglycemic agents, the doses of which 
might have to be increased, and which might 
sometimes have to be replaced with insulin(45); 
protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors, although efavirenz or 
a combination of saquinavir and ritonavir can 
be used without the need for discontinuing 
rifampin(46); oral anticoagulants, the doses of 
which should be carefully monitored, as should 
their international normalized ratios; and other 
drugs, such as valproic acid, antidepressants 
(nortriptyline and sertraline), barbiturates, 
benzodiazepines, beta-adrenergic blocking 
agents, ketoconazole, chloramphenicol, 
contraceptives, corticosteroids, cyclosporine, 
dapsone, digoxin, diltiazem, enalapril, phenytoin, 
fluconazole, haloperidol, itraconazole, 
macrolides, nifedipine, quinidine, rapamycin, 
simvastatin, theophylline, and verapamil.(3,6,7,47) 
The administration of rifampin in combination 
with ketoconazole or para-aminosalicylic acid 
decreases the serum levels of rifampin. The 
drugs should be administered separately, at least 
12 h apart.(48,49)
Pyrazinamide
Pyrazinamide is a nicotinic acid derivative, 
the molecular structure of which is similar to 
that of isoniazid. However, there is no cross-
resistance of M. tuberculosis to pyrazinamide 
and isoniazid. Pyrazinamide was synthesized in 
1936 and has been used as an antituberculosis 
drug since 1952. The MIC of pyrazinamide for 
M. tuberculosis is 6.25-50.0 µg/mL at a pH of 
5.5. After oral administration, pyrazinamide is 
well absorbed and widely distributed throughout 
the body. The plasma concentration of the 
drug peaks within 2 h after its administration. 
Pyrazinamide is bactericidal and has a potent 
sterilizing effect, principally in the acid medium 
within macrophages and at sites of acute 
neonates born to mothers who have been under 
treatment with isoniazid should be given vitamin 
K, in order to avoid postpartum hemorrhage.(42)
Use during breastfeeding
Although rifampin is compatible with 
breastfeeding, the infant should be monitored 
for jaundice.(5,32)
Use in patients with liver failure
Liver failure can impair rifampin clearance, 
increasing the serum levels of the drug. However, 
due to the important role that rifampin plays 
in tuberculosis treatment regimens, the drug 
is generally included, with the proviso that the 
patients be closely monitored through frequent 
clinical evaluations and laboratory tests (see also 
Drug-induced hepatitis).(3)
Use in patients with kidney failure
Because rifampin is metabolized in the liver, 
the drug can be used at full doses in patients 
with kidney failure.(3-5)
Interactions
Foods
Rifampin should be taken on an empty 
stomach. Foods decrease the absorption of the 
drug by as much as 26%, as well as increasing 
the time required for the drug to reach maximum 
concentration and decreasing that concentration 
by 15-36%.(35)
Antacids
Antacids containing aluminum hydroxide 
delay the absorption of rifampin.(35)
Other drugs
A large number of interactions can occur 
between rifampin and other drugs. The drug is a 
potent inducer of the CYP450 system, including 
the CYP3A and CYP2C subfamilies, which 
account for more than 80% of the CYP450 
isoenzymes. Therefore, rifampin can increase the 
metabolism of numerous drugs that are partially 
or completely metabolized by CYP450 when 
these drugs are administered concomitantly 
with rifampin. In addition, rifampin induces 
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Adverse effects
Minor adverse effects
• Gastrointestinal symptoms: Nausea, 
vomiting, and anorexia are common in 
patients treated with pyrazinamide.(3,7) 
• Hyperuricemia and arthralgia in non­gouty 
individuals: In non-gouty patients receiving 
pyrazinamide, hyperuricemia commonly 
leads to arthralgia. The mechanism is 
related to pyrazinoic acid, the principal 
metabolite of pyrazinamide, which inhibits 
the renal tubular secretion of uric acid. 
This rarely requires that pyrazinamide 
be discontinued or that the dose be 
adjusted. The hyperuricemia is typically 
asymptomatic, and the pain responds well 
to treatment with aspirin or nonsteroidal 
anti-inflammatory drugs.(3,7,13) 
• Exanthema and pruritus: Exanthema and 
pruritus are relatively common effects of 
pyrazinamide administration. In most cases, 
these improve with the administration of 
antihistamines.(3,7) 
• Dermatitis: Treatment with pyrazinamide 
can cause photosensitivity dermatitis.(3) 
Major adverse effects
• Severe exanthema and pruritus: If 
severe exanthema and pruritus occur, 
pyrazinamide should be discontinued.(3,7) 
• Rhabdomyolysis with myoglobinuria 
and kidney failure: Rhabdomyolysis 
with myoglobinuria and kidney failure 
is a rare complication of pyrazinamide 
treatment and requires that the drug be 
discontinued. 
• Acute arthritis in gouty individuals: In 
patients receiving pyrazinamide, acute 
arthritis is rare, except in those with a history 
of gout. The symptoms improve with the 
use of moisturizers and allopurinol, as well 
as with dietary changes.(3,7) 
• Hepatotoxicity: Pyrazinamide is the most 
hepatotoxic of the drugs cited in the 
present study. Therefore, it is essential that 
the doses of the drug be adjusted to the 
weight of the patient. Liver impairment 
is rare if the drug is administered at a 
maximum dose of 35 mg • kg−1 • day−1. 
The new guidelines for the treatment of 
inflammation. In patients with tuberculosis-
induced lung injury, the growth of the bacilli 
that are phagocytosed by macrophages is 
inhibited by the acid environment within the 
phagolysosomes. Growth is also inhibited in the 
inflammatory zones of the cavitary wall due to the 
acid pH in those zones. These bacilli (designated 
persistent bacilli in the sporadic multiplication 
phase) are responsible for bacteriological 
relapse. Pyrazinamide is the most effective drug 
in eliminating this population. This sterilizing 
activity of pyrazinamide allows the duration 
of the treatment with the RHZ regimen to be 
reduced to six months.(3,50,51) M. tuberculosis is 
the only microorganism that is susceptible to 
pyrazinamide.(50,51)
Mechanism of action
Pyrazinamide is a prodrug that needs to 
be converted into its active form, pyrazinoic 
acid, by bacterial enzymes (nicotinamidase/
pyrazinamidase). The mechanism of action of 
pyrazinamide has yet to be fully understood. It is 
supposed that pyrazinamide enters the bacillus 
passively, is converted into pyrazinoic acid by 
pyrazinamidase, and reaches high concentrations 
in the bacterial cytoplasm due to an inefficient 
efflux system. The accumulation of pyrazinoic 
acid decreases the intracellular pH to levels that 
cause the inactivation of enzymes—such as fatty 
acid synthase I, which plays a fundamental role 
in synthesizing fatty acids—and, consequently, 
the impairment of mycolic acid biosynthesis. 
Resistance to pyrazinamide results from 
mutations in the pncA gene, which encodes 
the nicotinamidase/pyrazinamidase enzyme and 
prevents pyrazinamide from being converted 
into its active form.(50,52,53)
Metabolization and excretion
Pyrazinamide is metabolized in the liver, 
and 70% of the drug is excreted in urine 
(3% in non-metabolized form), principally 
through glomerular filtration. The half-life of 
pyrazinamide is 9-10 h but can be as long as 
26 h in patients with kidney failure if the doses 
are not adjusted.(3,51)
Central nervous system 
Pyrazinamide crosses the blood-brain barrier, 
and the concentrations of the drug in the CSF 
are similar to those in plasma.(3,51)
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Antacids
Antacids do not interfere with the absorption 
of pyrazinamide.(35)
Other drugs
Probenecid, rifampin, isoniazid, and 
ethionamide can potentiate the toxic effects of 
pyrazinamide. The combination of pyrazinamide 
and zidovudine can reduce the effect of 
pyrazinamide. Pyrazinamide antagonizes the 
effects of probenecid and decreases the serum 
concentration of cyclosporine. Pyrazinamide can 
increase the serum concentrations of uric acid, 
and it might be necessary to adjust the doses 
of allopurinol and colchicine in patients under 
gout treatment.(3,47,51)
Ethambutol
Ethambutol was synthesized in 1961 and has 
been used in the treatment of tuberculosis since 
1966. It acts on intracellular and extracellular 
bacilli, principally on rapidly growing bacilli. 
The MIC of ethambutol for M. tuberculosis is 
1-5 µg/mL. At the usual doses, ethambutol has 
a bacteriostatic effect.(3,15,54)
Mechanisms of action
Ethambutol interferes with the biosynthesis 
of arabinogalactan, the principal polysaccharide 
on the mycobacterial cell wall. Ethambutol 
inhibits the arabinosyltransferase enzyme 
encoded by the embB gene, which mediates the 
polymerization of arabinose into arabinogalactan. 
In vitro resistance to ethambutol develops slowly 
and is probably due to mutations in the embB 
gene.(15,50,54)
Metabolization and excretion
After the oral administration of ethambutol, 
75-80% of the dose is absorbed, and the serum 
levels of the drug peak within 2-4 h. A single 
25-mg/kg dose produces plasma concentrations 
of 2-5 µg/mL. The serum half-life of ethambutol 
is 3-4 h, and it can be as long as 10 h in patients 
with severe kidney failure. Part of the drug 
(20-30%) binds to plasma proteins. Ethambutol 
is widely distributed throughout the body, with 
the exception of the CSF in patients without 
meningitis. Ethambutol is metabolized in the 
tuberculosis in Brazil(1,2) recommend a 
dose of 1,600 mg for patients who weigh 
more than 50 kg, which is likely to reduce 
the hepatic adverse effects of the drug. 
In patients with pyrazinamide-induced 
hepatitis, the drug should be temporarily 
discontinued or even replaced.(7) 
Use during pregnancy
Pyrazinamide is a category C drug. The WHO 
considers it safe to use pyrazinamide during 
pregnancy. In Brazil, pyrazinamide has been used 
for more than two decades as part of regimen I 
(RHZ), and no risks have been reported.(7,30,51)
Use during breastfeeding
Although pyrazinamide is considered 
compatible with breastfeeding, the infant should 
be monitored for jaundice.(3,32,51)
Use in patients with liver failure
Pyrazinamide is a hepatotoxic drug, the 
effect of which is more evident in individuals 
with liver disease. These patients should 
be closely monitored and should undergo 
clinical examination and laboratory tests more 
frequently than is necessary for patients without 
liver disease.(3,7)
Use in patients with kidney failure
The metabolites of pyrazinamide are 
eliminated by the kidney and can accumulate in 
patients with kidney failure, which requires that 
the dose of the drug be decreased. The risk of 
developing pyrazinamide-induced hyperuricemia 
also increases in patients with kidney failure. 
The daily dose should be reduced to half when 
creatinine clearance is lower than 10 mL/min. 
Patients with creatinine clearance lower than 
30 mL/min or those on hemodialysis should be 
given pyrazinamide at a dose of 25-35 mg/kg, 
three times a week.(3,4,51)
Interactions
Foods
Foods have very little impact on the 
absorption of pyrazinamide. The drug can be 
taken at mealtime.(35)
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symptoms (nausea, vomiting, abdominal 
pain, and hepatotoxicity), hematological 
symptoms (eosinophilia, neutropenia, 
and thrombocytopenia), cardiovascular 
symptoms (myocarditis and pericarditis), 
neurological symptoms (headache, 
dizziness, and mental confusion), hyperu-
ri cemia/gout (due to a reduction in the 
excretion of uric acid by the kidney), 
hypersensitivity (skin rash, arthralgia, 
and fever), and (occasionally) pulmonary 
infiltrates.(3,40,51,54) 
Use during pregnancy
Ethambutol is a category B1 drug. Ethambutol 
crosses the placental barrier, and the plasma 
concentration of ethambutol in the fetus can be 
as high as 30% of the plasma concentration of 
the drug in the mother. The WHO considers it 
safe to use ethambutol during pregnancy.(3,51)
Use during breastfeeding
Ethambutol concentrations in breast milk 
are similar to the plasma concentrations of 
the drug. The American Academy of Pediatrics 
considers ethambutol to be compatible with 
breastfeeding.(32)
Use in patients with liver failure
Ethambutol can be used at full doses in 
patients with liver failure. It is not necessary to 
adjust the dose of the drug in such patients.(3,51)
Use in patients with kidney failure
Ethambutol and its metabolites can 
accumulate in patients with kidney failure. 
Patients with a creatinine clearance of 
30-50 mL/min should use the drug at longer 
intervals between doses, usually every 36 h. In 
patients on hemodialysis or in those in whom 
creatinine clearance is lower than 30 mL/min, 
a dose of 15-20 mg/kg should be administered 
three times a week. Ethambutol is removed by 
peritoneal dialysis and, to a lesser degree, by 
hemodialysis.(3,4,57)
Interactions
Foods
Foods have a minimal effect on the 
bioavailability of ethambutol.(35)
liver, and the principal mechanism is oxidation 
to form an intermediate aldehyde, followed by 
conversion into dicarboxylic acid. Most of the 
drug (50-80%) is excreted in urine (8-15% is 
excreted as metabolites), and 20% is excreted in 
feces.(3,40,51,54)
Central nervous system 
Ethambutol does not cross healthy meninges. 
In cases of meningitis, the CSF levels of 
ethambutol are at 10-50% of the plasma levels 
of the drug.(3,40,51)
Adverse effects
Ethambutol is generally well tolerated. Most 
adverse effects are dose- and time-dependent, 
being more common at doses higher than 
15 mg/kg.
• Retrobulbar neuritis: When retrobulbar 
neuritis occurs in patients treated with 
ethambutol, it is generally reversible and 
depends on the dose and duration of 
administration. The central fibers of the 
optic nerve are most commonly affected, 
causing symptoms of blurred vision; 
ophthalmologic examination reveals a 
decrease in visual acuity, presence of 
scotomas, and loss of the ability to discern 
the color green and, in some cases, the 
color red. Peripheral fiber impairment is 
less common and manifests as a reduction 
in the visual field. The reaction is dose-
dependent. The risk is small (1%) when 
ethambutol is administered at doses of 
15 mg • kg−1 • day−1. However, retrobulbar 
neuritis occurs in 15-18% of patients 
receiving doses of 35 mg • kg−1 • day−1 for 
more than two months. In addition, the 
risk of developing retrobulbar neuritis is 
greater in patients with kidney failure and 
in elderly individuals with impaired renal 
function. Retrobulbar neuritis is reversible 
when the symptoms are detected early and 
the drug is immediately discontinued. The 
administration of ethambutol should be 
avoided in young children, whose visual 
acuity is difficult to evaluate.(3,40,51,54-56) 
Peripheral neuritis: In rare cases, treatment 
with ethambutol causes peripheral neuritis, 
the symptoms of which improve after 
administration of pyridoxine.(3,40,51) 
• Other effects: Additional effects of etham­
butol administration include gastrointestinal 
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the initiation of treatment and can be classified 
as mild (hepatic enzyme levels three to five times 
higher than normal), moderate (hepatic enzyme 
levels up to ten times higher than normal), or 
severe (hepatic enzyme levels more than ten 
times higher than normal).
Pyrazinamide is considered the most 
hepatotoxic drug of the basic regimen, and 
pyrazinamide-induced hepatotoxicity is dose-
dependent. Because the risk increases when 
the dose is higher than 30 mg • kg−1 • day−1, 
the dose must be adjusted to the weight of the 
patient.
The administration of isoniazid in isolation, 
at doses adjusted to the weight of the patient, 
rarely produces drug-induced hepatitis, which is 
practically nonexistent in children but is more 
common in alcoholic and elderly individuals. 
Hepatocyte injury caused by isoniazid seems to 
be more closely related to the formation of the 
hydrazine radical produced by direct metaboli-
zation of the drug. The histopathological 
characteristics of isoniazid-induced hepatitis can 
include acute cellular necrosis or cholestasis. In 
patients with cholestasis, clinical manifestations 
occur earlier due to sensitization mechanisms 
that are evidenced (through laboratory testing) by 
an increase in bilirubin and alkaline phosphatase 
levels. Patients with cholestatic hepatitis have 
a better prognosis. Acute cellular necrosis is 
indistinguishable from viral hepatitis, which 
is why extremely high aminotransferase levels 
can be found. In these cases, serology for viral 
hepatitis should be ordered. When administered 
in combination with rifampin, isoniazid can lead 
to acute, fatal drug-induced hepatitis, which is 
fortunately rare. Especially when administered 
in combination with rifampin, isoniazid 
can reactivate inapparent viral infections in 
asymptomatic patients and therefore cause the 
onset of viral hepatitis, usually hepatitis B.
The administration of rifampin in isolation 
rarely causes liver changes. It can, however, 
potentiate the hepatotoxic effect of isoniazid, 
since rifampin induces hepatic microsomal 
enzymes of CYP450 that, in turn, facilitate the 
conversion of isoniazid into monoacetylhydrazine 
and hydrazine (toxic metabolites of isoniazid). 
These agents are implicated in the pathogenesis 
of liver necrosis. There has been no statistical 
confirmation that the incidence of hepatotoxicity 
is higher in individuals with the rapid acetylator 
Antacids
Antacids can reduce the maximum 
concentration of ethambutol by as much as 28%. 
The drugs should therefore be administered at 
longer intervals.(35)
Other drugs
Ethionamide can exacerbate the toxic effects 
of ethambutol.(58)
Drug-induced hepatitis due to 
interactions among antituberculosis 
drugs
Three of the drugs that constitute the basic 
regimen proposed by the Brazilian National 
Ministry of Health (rifampin, isoniazid, and 
pyrazinamide) are potentially hepatotoxic. These 
drugs are metabolized in the liver. The three 
drugs interact with one another and with other 
drugs, which occasionally increases the risk of 
hepatotoxicity. The predisposing factors for 
hepatotoxicity include genetic causes, advanced 
age, extent of the disease, female gender, 
nutritional status, excessive doses of the drugs, 
use in combination with other hepatotoxic drugs, 
alcoholism, chronic viral hepatitis (types B and 
C), and HIV infection. Approximately 5% of the 
tuberculosis patients who use the RHZ regimen 
present with a three- to five-fold increase in 
hepatic enzyme levels, as well as with increased 
bilirubin levels, without clinical manifestations. 
These levels decrease spontaneously as the 
treatment progresses. According to the 
international literature, in patients using these 
medications, the mean risk of developing drug-
induced hepatitis is 1-10%, depending on 
factors such as race, socioeconomic status, and 
geographic location. Drug-induced hepatitis, 
including hepatitis due to antituberculosis 
drugs, might be related to mechanisms of 
hypersensitivity to drugs that are intrinsically 
hepatotoxic or to drugs that can produce a 
toxic metabolite that liver tissue might not be 
able to clear. Antituberculosis drug-induced 
cholestasis can be accompanied by early clinical 
manifestations, such as increased bilirubin levels 
and increased alkaline phosphatase levels, the 
prognosis of the latter being better than that of 
the former. Most of the cases of drug-induced 
hepatotoxicity occur within two months after 
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by one at weekly intervals. Because rifampin 
(with or without ethambutol) is the most potent 
and least hepatotoxic drug in the regimen, 
the ATS/CDC/IDSA guidelines,(3) as well as the 
III Brazilian Thoracic Association Guidelines 
on Tuberculosis,(2) recommend that rifampin 
be the first drug to be reintroduced, followed 
by isoniazid and pyrazinamide. In cases of 
intolerance to one of the drugs, the III Brazilian 
Thoracic Association Guidelines on Tuberculosis 
recommend that the following regimens be 
used: a) intolerance to rifampin: 2HZES5\10HE, 
b) intolerance to isoniazid: 2RZES5\7RE, 
c) intolerance to pyrazinamide: 2RHE\7RH, 
d) intolerance to ethambutol: 2RHZ\4RH(1-3,10,59-63)
Final considerations
The treatment of tuberculosis can cause 
adverse reactions. The management of situations 
that are more severe (which are, fortunately, 
uncommon) is generally the responsibility of 
referral centers and experienced professionals 
with knowledge of the therapeutic alternatives 
available.
Accurate diagnoses and knowledge of the 
pharmacological properties of the drugs involved 
allow professionals to tailor their approach to 
each individual case.
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